drugset / Trial / NCT02109861
Microdose Study of Melphalan, Bortezomib and Dexamethasone
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The purpose of the study is to identify specific genes that are up- or downregulated in multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib (Velcade®) or Dexamethasone (Dexaven®). The study treatment constitutes 1% of the planned standard myeloma treatment and will be given two hours prior to standard treatment. Blood samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.013 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 0.4 mg | Intravenous |
| Subject | Melphalan | Small molecule | 2 mg/m2 | Intravenous |